Pellegen® is a bioactive inorganic chemical in the class of silicon substituted phosphates (SSPs). Aiding in the the regeneration of in vivo tissue that it is in contact with, it is biologically inductive. Acting by modulating multiple cellular growth and differentiation factors, it also has been shown to affect gene expression. Because of its mechanism of action at the cellular biochemical level, it must be administered or applied in the fluid surrounding cells making its ionic content available for cellular regulation. Whether on oral mucosa, broken skin, i.e. ulcers, etc., or placed surgically, the various formulations of this class can assist the repair of the range of musculoskeletal tissue types. The composition of Pellegen® has been shown over a long history to have a significant effect on tissue regeneration across the widest range of tissue types.
In the early 1970s, the successful use of SSPs of the composition of Pellegen® was demonstrated clinically. Used in orthopaedics, it statistically reduces the incidence of non-union fractures in trauma. Additionally, the inherent antimicrobial activity of SSPs makes them particularly useful in orthopaedics. Also, in other bone applications, it is clinically used as filling material in benign tumor surgery, for reconstruction of defects in facial bones, for treatment of periodontal bone defects, in repairing orbital “blowout” fractures, in spinal fusion, and for reconstruction of the iliac crest defect after bone graft harvesting, among a few of the FDA approved applications.
Perhaps, the widest successful use of SSPs has been in dental medicine. Here, the ability of SSPs to successfully reconstitute bone / tissue interfaces was proven in periodontal disease adding to all the other bone uses. This soft tissue to bone connectivity was further confirmed by the ENT use in tympano-ossicle reconstruction. Anchoring dental implants in the high-load, contaminated, alveolar ridge has led researchers to prosthetic fixation success in orthopaedics preventing loosening.
With many other FDA approved dental applications exposing SSPs to oral ingestion, the safety profile of SSPs is confirmed without exception since first being used in the 1970s. Now manufactured by the ton for FDA approved dental medicine, safety without allergenic response is magnified by the voluminous exposure over the extended time. There have been no adverse events reported due to the chemical composition of SSPs.
In tissue engineering, some of the most challenging problems include delivery of cellular mediators of growth and differentiation factors to sites for repair and regeneration, controlled release of factors, persistence of factor activity at the site of delivery allowing continuation of healing, and perhaps most limiting is cost. Most in-vivo normal mechanisms of cellular repair and maintenance depend on a time dependent, quantitative, and qualitative sequence supplying a constant delivery of thousands of interrelated factors produced by a renewable responsive complex of intracellular chemical pathways. The half-life of many of the multitudes of these chemicals is often measured in seconds. For example, the half-life of rhBMP is ~20-30 seconds. With a cost of thousands of dollars, kick starting one segment of a complex metabolic pathway is, to say the least, very risky.
SSPs address many of these problems and limitations. They are easily placed directly on tissues such as open skin or the oral mucosa or applied in surgical procedures, mixed with carriers, or incorporated in or on devices, etc. Adding SSPs to resorbable fixation plates and screws, etc. with various compositions such as polylactic /polyglycolic acid formulations imparts benefits to the devices such as preventing granulation and increasing rate of substitution by normal healed tissue. Used as in dental implants, they fix the prosthesis to bone. All of these attributes are made possible by a persistence of the SSP where placed without it interfering with normal metabolism. Controlled release is made possible by forming the glass matrix at 1350℃. Elution of the ionic dissolution products (e.g. calcium, phosphorus, silicon, and sodium) in the SiO2-CaO-Na2O-P2O5 system continues for months culminating in complete absorption. This material when used to implant a total joint costs less than $100 while preventing all the consequences and complications associated with particulate loosening.
Treatment / Application
Ease of use is a hallmark of SSPs. For diabetic ulcers, the wound must be debrided using the roughness of a gauze 4 X 4 pad, and cleansed with an aqueous, water miscible solution such as hydrogen peroxide. Pellegen® is applied in a single granular layer and covered with a gauze pad[s]. As long as the wound remains free of necrotic material, fibrin, etc., and there is Pellegen® visible, it is not necessary to either add more Pellegen® or redebride the wound. It is difficult to use either too much or too little Pellegen®. Preferably, there is a single layer of the granular matrix, and not an excess retaining tissue fluid. Too much material, also, does not allow the wound to “breathe”.
Infection in the surrounding tissue should be appropriately topically, orally, parenterally treated with the lowest generation antibiotic to which the cultured pathogen is susceptible. As SSPs are inherently antimicrobial, it is not necessary to use any antibiotic directly on the wound. Water miscible products such as 1-2% acetic acid on burns to prevent Pseudomonas may be used in place of peroxide or normal saline, etc.
Adverse reactions / Complications
In the decades of use of SSPs, there have been no adverse reactions to the chemical composition of Pellegen®. Like sand, there is potential for mechanical irritation, which is simply treated by removal from the site. SSPs are non-allergenic. Particles may be inhaled, but are cleared by coughing, and are ultimately completely absorbed.
- Alexander Hoppe, Viviana
Mouriñob, Aldo R. Boccaccini, Therapeutic inorganic ions in bioactive
glasses to enhance bone formation and beyond, Biomater. Sci., 2013, 1,
254–256
- Mohamed N. Rahamana, Delbert E. Day, B. Sonny Bal, Qiang Fuc, Steven
B. Jung, Lynda F. Bonewald, Antoni P. Tomsia, Bioactive glass in tissue
engineering, Acta Biomater. 2011 June ; 7(6): 2355–2373
- Satadru Kashyap, Effect of
crystallinity on crack propagation and mineralization of bioactive
glass, M.S. thesis in Materials Engineering, University of Alberta,
Department of Chemical and Materials Engineering, Fall 2010
- Ensanya A. Abou Neel, David M.Pickup, Sabeel P. Valappil,
Robert J. Newport, Jonathan C. Knowles, Bioactive functional materials: a
perspective on phosphate-based glasses, J. Mater. Chem., 2009, 19,
690-701
- Elsie S. Place, Nicholas D. Evans, Molly M. Stevens, Complexity in
biomaterials for tissue engineering, Nature Materials 8, 457 – 470
(2009)
- Laurencin C, Khan Y, El-Amin SF. Bone graft substitutes. Expert Rev Med Devices 2006; 3 : 49-57.
- S. Lee et al. Bioactive Glasses: A Potential New Class of Active Ingredients for Personal Care, SÖFW 129, 9, 2003
- Gazdag AR, Lane JM, Glaser D, Forster RA. Alternatives to autogenous
bone graft : efficacy and indications. J Am Acad Orthop Surg 1995; 3 :
1-8.
- Marsh JL. Principles of bone grafting: non-union, delayed union. Surgery 2006; 24 : 207-10.
- J. Kent Leach, Darnell Kaigler, Zhuo Wang, Paul H. Krebsbach, David
J. Mooney, Coating of VEGF-releasing scaffolds with bioactive glass for
angiogenesis and bone regeneration, Biomaterials 27 (2006) 3249–3255
- Finkemeier CG. Bone-grafting and bone-graft substitutes. J Bone Joint Surg Am 2002; 84A : 454-64.
- Marx RE. Bone and bone graft healing. Oral Maxillofac Surg Clin North Am 2007; 19 : 455-66; v.
- Kettunen J, Makela EA, Turunen V, Suomalainen O, Partanen K.
Percutaneous bone grafting in the treatment of the delayed union and
non-union of tibial fractures. Injury 2002; 33 : 239-45.
- Jebahi S, Farhat L, Oudadesse H, Rebai T, El Feki A, Jamel Doued,
Hassib Keskes, Molecular biological and advances in materials, JSIR
2014; 3(2): 265-272
- Habibovic P, de Groot K. Osteoinductive biomaterials – properties
and relevance in bone repair. J Tissue Eng Regen Med 2007; 1 : 25-32.
- Lieberman JR, Ghivizzani SC, Evans CH. Gene transfer approaches to the healing of bone and cartilage. Mol Ther 2002; 6 : 141-7.
- Xynos I. D., Edgar A. J., Buttery L. D. K., Hench L. L., Polak J. M.
2001. Gene-expression profiling of human osteoblasts following
treatment with the ionic products of Bioglass 45S5 dissolution. J.
Biomed. Mater. Res. A 55, 151–157
- Van der Kraan PM, Buma P, van
Kuppevelt T, van Den Berg WB. Interaction of chondrocytes, extracellular
matrix and growth factors: relevance for articular cartilage tissue
engineering. Osteoarthritsis Cartilage 2002; 10 : 631-7.
- Einhorn TA, Majeska RJ, Rush EB, Levine PM, Horowitz MC. The
expression of cytokine activity by fracture callus. J Bone Miner Res
1995; 10 : 1272-81.
- Hunziker EB. Growth factor-induced healing of partial-thickness
defects in adult articular cartilage. Osteoarthritis Cartilage 2001; 9 :
22-32.
- Richard M. Day, Bioactive Glass Stimulates the Secretion of
Angiogenic Growth Factors and Angiogenesis in Vitro, Tissue Engineering.
May/June 2005, 11(5-6): 768-777
- Fujimoto E, Ochi M, Kato Y, Mochizuki Y, Sumen Y, Ikuta Y.
Beneficial effect of basic fibroblast growth factor on the repair of
full-thickness defects in rabbit articular cartilage. Arch Orthop Trauma
Surg 1999; 119 : 139-45.
- Weisser J, Rahfoth B, Timmermann A, Aigner T, Brauer R, von der Mark
K. Role of growth factors in rabbit articular cartilage repair by
chondrocytes in agarose. Osteoarthritis Cartilage 2001; 9 (Suppl A) :
548-54.
- Tang CH, Yang RS, Huang TH,
Liu SH, Fu WM. Enhancement of fibronectin fibrillogenesis and bone
formation by basic fibroblast growth factor via protein kinase
c-dependent pathway in rat osteoblasts. MolPharmacol 2004; 66 : 440-9.
- Geiger F, Lorenz H, Xu W, Szalay K, Kasten P, Claes L, et al. VEGF
producing bone marrow stromal cells (BMSC) enhance vascularization and
resorption of a natural coral bone substitute. Bone 2007; 41 : 516-22.
- Chen Y. Orthopedic applications of gene therapy. J Orthop Sci 2001; 6 : 199-207.
- Prelle K, Wobus AM, Krebs O, Blum WF, Wolf E. Overexpression of
insulin-like growth factor-II in mouse embryonic stem cells promotes
myogenic differentiation. Biochem Biophys Res Commun 2000; 277 : 631-8.
- Kramer J, Hegert C, Guan K,
Wobus AM, Miiller PK, Rohwedel J. Embryonic stem cell-derived
chondrogenic differentiation in vitro: activation by BMP-2 and BMP-4.
Mech Dev 2000; 92 : 193-205.
- Lumelsky N, Blondel O, Laeng
P, Velasco I, Ravin R, McKay R. Differentiation of embryonic stem cells
to insulin-secreting structures similar to pancreatic islets. Science
2001; 292 : 1389-93.
- Caplan, AI, Elyaderani M,
Mochizuki Y, Wakitani S, Goldberg VM. Principles of cartilage repair and
regeneration. Clin Orthop Relat Res 1997; 342 : 254-69.
- Lind M, Bunger C. Orthopaedic applications of gene therapy. Int Orthop 2005; 29 : 205-9.
- Martinek V, Fu FH, Lee CW, Huard J. Treatment of osteochondral
injuries. Genetic engineering. Clin Sports Med 2001; 20 : 403-16; viii.
- Truumees, E, Herkowitz HN. Alternatives to autologous bone harvest in spine surgery. Orthop J 1999; 12:77-88.
- Hak DJ. The use of osteoconductive bone graft substitutes in orthopaedic trauma. J Am Acad Orthop Surg 2007; 15:525-36.
- Noshi T, Yoshikawa T, Ikeuchi M, Dohi Y, Ohgushi H, Horiuchi K, et
al. Enhancement of the in vivo osteogenic potential of
marrow/hydroxyapatite composites by bovine bone morphogenetic protein. J
Biomed Mater Res 2000; 52 : 621-30.
- Yoneda M, Terai H, Imai Y,
Okada T, Nozaki K, Inoue H, et al. Repair of an intercalated long bone
defect with a synthetic biodegradable bone-inducing implant.
Biomaterials 2005; 26 : 5145-52.
- Hench LL, Splinter RJ, Allen
WC, Greenlee TK Jr. Bonding mechanisms at the interface of ceramic
prosthetic materials. J Biomed Mater Res Symp 1971; 2:117-41.
- Dorea HC, McLaughlin RM,
Cantwell HD, Read R, Armbrust L, Pool R, et al. Evaluation of healing in
feline femoral defects filled with cancellous autograft, cancellous
allograft or Bioglass. Vet Comp Orthop Traumatol 2005; 18 : 157-68.
- Hench LL, Wilson J. Surface-active biomaterials. Science 1984; 226 : 630-6.
- Brink M, Turunen T, Happonen
RP, Yli-Urpo A. Compositional dependence of bioactivity of glasses in
the system [Na.sub.2]O-[K.sub.2]O-MgO-CaO-[B.sub.2][O.sub.3]-[P.sub.2]
[O.sub.5]-Si[O.sub.2]. J Biomed Mater Res 1997; 37 : 114-21.
- De Aza PN, Luklinska ZB,
Santos C, Guitian F, De Aza S. Mechanism of bone-like formation on a
bioactive implant in vivo. Biomaterials 2003; 24 : 1437-45.
- Reck R. Bioactive glass ceramic: a new material in tympanoplasty. Laryngoscope 1983; 93 : 196-9.
- Heikkila JT, Mattila KT,
Andersson OH, Knuuti J, Yli-Urpo A, Aho AJ. Behaviour of bioactive glass
in human bone. In: Wilson J, Hench LL, Greenspan D, editors.
Bioceramics vol. 8. Great Britain : Elsevier Science, Oxford; 1995. p.
35-40.
- Kinnunen I, Aitasalo K,
Pollonen M, Varpula M. Reconstruction of orbital floor fractures using
bioactive glass. J Craniomaxillofac Surg 2000; 28 : 229-34.
- Aitasalo K, Kinnunen I,
Palmgren J, Varpula M. Repair of orbital floor fractures with bioactive
glass implants. J Oral Maxillofac Surg 2001; 59 : 1390-5; disussion
1395-6.
- Ido K, Asada Y, Sakamoto T,
Hayashi R, Kuriyama S. Radiographic evaluation of bioactive
glass-ceramics grafts in postero-lateral lumbar fusion. Spinal Cord
2000; 38 : 315-8.
- Green DW. Tissue bionics : examples in biomimetic tissue engineering. Biomed Mater 2008; 3 : 034010